CytoSorbents Q2 revenue $9.6M (+9% YoY); net income $1.9M but adjusted loss widens

Cytosorbents Corp

2025-Q2 EPS reported $0.01 vs consensus -$0.05 ▲ beat (+119.6%)

Revenue $9.6M, up 9% YoY (4% constant currency); Germany sales up 22% YoY and sequentially.
Net income $1.9M ($0.03/share) vs net loss $4.3M in Q2 2024; adjusted net loss $3.7M vs $2.8M.
Adjusted EBITDA loss $2.6M vs $2.2M in Q2 2024; cash $11.7M at quarter end.
FDA appeal for DrugSorb-ATR held in July; administrative review expected by end of August 2025.
Health Canada reconsideration filed; will proceed after FDA decision.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.